NEW YORK–(BUSINESS WIRE)–Rumi Therapeutics, a drug-development company within Rumi Scientific Holdings, today announced an option to license agreement with Enthorin Therapeutics to advance RTX-7340 (ENT-7340), an investigational phosphodiesterase 2 (PDE2) inhibitor, for the treatment of Fragile X syndrome (FXS). The agreement brings an IND-ready therapeutic candidate into Rumi Therapeutics’ pipeline and represents a significant milestone in Rumi Scientific Holdings’ expansion from discovery-s